abrdn Healthcare Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-30 09:05:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.
- During the first quarter of 2025, we made several changes to the portfolio.
- The top three detractors were Sarepta Therapeutics, Regeneron Pharmaceuticals and Vaxcyte.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.[1]...
Read the full article on Seeking Alpha
For further details see:
abrdn Healthcare Investors Q1 2025 Commentary
Tekla World Healthcare Fund Shares of Beneficial Interest
NASDAQ: THW
THW Trading
0.12% G/L:
$12.145 Last:
79,823 Volume:
$12.13 Open:
THW Latest News
March 10, 2026 04:17:00 pm
Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
January 12, 2026 04:17:00 pm
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
June 10, 2025 04:17:00 pm
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
